GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

Phase 2

Completed

Conditions: Hyperhidrosis

Interventions: Drug: Vehicle
Drug: Umeclidinium

First Posted Date: 2015-09-30

Last Posted Date: 2018-10-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT02563899

Locations: 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada

A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria

Phase 2

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Tafenoquine
Drug: Chloroquine

First Posted Date: 2015-09-30

Last Posted Date: 2020-11-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT02563496

Locations: 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam

DUAC® Early Onset Efficacy Study in Japanese Subjects

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Duac® fixed dose combination gel
Drug: ADA 0.1% gel
Drug: CLDM 1% gel

First Posted Date: 2015-09-23

Last Posted Date: 2018-08-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 350

Registration Number: NCT02557399

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

Phase 3

Completed

Conditions: Asthma

Interventions: Biological: Mepolizumab 100mg
Drug: Placebo

First Posted Date: 2015-09-21

Last Posted Date: 2020-02-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 306

Registration Number: NCT02555371

Locations: 🇺🇦
GSK Investigational Site, Vinnytsia, Ukraine

A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children

Not Applicable

Withdrawn

Conditions: Growth and Development

Interventions: Dietary Supplement: Control
Dietary Supplement: Test Product

First Posted Date: 2015-09-16

Last Posted Date: 2017-12-20

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02551627

Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Procedure: Lipopolysaccharide challenge
Procedure: Saline challenge
Procedure: Labelled neutrophils and Imaging assessment

First Posted Date: 2015-09-16

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 46

Registration Number: NCT02551614

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients

Phase 1

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: [11C]-GSK2256098 500 MBq

First Posted Date: 2015-09-16

Last Posted Date: 2018-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 10

Registration Number: NCT02551653

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: GSK2981278 0.03%
Drug: GSK2981278 0.1%
Drug: GSK2981278 0.8%
Drug: GSK2981278 4%
Drug: Vehicle
Drug: Betamethasone valerate 0.1%

First Posted Date: 2015-09-14

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15

Registration Number: NCT02548052

Locations: 🇩🇪
GSK Investigational Site, Hamburg, Germany

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

Phase 2

Completed

Conditions: Virus Diseases

Interventions: Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Biological: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine